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To the Editor, 
 
We are compelled to comment on a recent article in your journal “C60 Exposure Augments 
Cardiac Ischemia/Reperfusion Injury and Coronary Artery Contraction in Sprague Dawley Rats; 
138(2), 365–378” by Thompson1 in which various conclusions were made concerning the 
toxicity of C60. In this study, insoluble C60 was mixed with polyvinylpyrrolidone (PVP) and used 
to challenge rats which were then surgically induced to examine various cardiovascular toxicity 
parameters. Both intravenously (IV) and intratracheally (IT) exposure to the C60-PVP mixture 
resulted in expansion of myocardial infarction in male and female rats following I/R injury, 
elevated inflammatory cytokines, and augmented vasocontraction of coronary arteries. 
 




To the Editor, 
 
We are compelled to comment on a recent article in your journal “C60 Exposure Augments 
Cardiac Ischemia/Reperfusion Injury and Coronary Artery Contraction in Sprague Dawley Rats; 
138(2), 365–378” by Thompson1 in which various conclusions were made concerning the 
toxicity of C60. In this study, insoluble C60 was mixed with polyvinylpyrrolidone (PVP) and used 
to challenge rats which were then surgically induced to examine various cardiovascular toxicity 
parameters. Both intravenously (IV) and intratracheally (IT) exposure to the C60-PVP mixture 
resulted in expansion of myocardial infarction in male and female rats following I/R injury, 
elevated inflammatory cytokines, and augmented vasocontraction of coronary arteries. 
 
Previous studies in which the starting material used for the experiments consisted of 
uncharacterized and impure fullerene-containing mixtures, have led to erroneous results 
suggesting fullerenes, rather than the impurities, large particle sizes, and many isomers, induced 
the toxicological effects.2,3 Similarly, in this study insoluble C60 is mixed with PVP and this 
mixture is used for the in vitro and in vivo studies. Unfortunately, although the manuscript 
suggests that one can find “more information about our formulation of C60 in the Supplementary 
Data,” no such data are presented. Thus, the relevance of the conclusions interpreted using the 
test materials is unclear for several reasons. 
 
First, the exact nature of the starting material is not clear. For example, is the C60inside the PVP 
or coated with it? Does the C60 stay bound to PVP in serum? If not, then C60 will simply 
precipitate out in the blood. Although the title and the manuscript continuously state C60 (not 
C60 plus PVP) as the substance being studied the authors are not observing data revealed through 
C60 exposure; rather they are observing data from a mixture of insoluble C60 plus PVP which 
together make a completely new molecular entity or entities. The authors fully acknowledge that 
the insolubleness of C60 “due to its hydropho-bicity” was the reason it was formulated with PVP. 
 
Second, proper controls were not included. Although controls for PVP were performed, there 
were no controls performed to conclude it was something specific about the nature/structure of 
the C60 as any amorphous carbon nanoparticle milieu with the same incredibly large size (up to 
800 nm particles) would in all likelihood invoke the same response indicated in these studies. 
 
Third, in addition to the difficulties of injecting large, amorphous, aggregates directly into the 
circulatory or respiratory systems, the fact that C60 particles are not water soluble raises 
toxicological issues that should not be surprising to anyone; ingestion of insoluble material 
causes various toxicological stresses. Thompson et al.'s study reveals no evidence that the 
induced inflammation and exacerbated cardiac injury is a result of fullerenes, however, suggests 
a correlation between inflammation and cardiac injury induced via large agglomerates of 
particles. This is further supported by the author's citations within the introduction.4–6 
 
Given the questionable starting material used, we refute the misleading conclusion that 
“C60 exposure of Sprague Dawley rats resulted in deleterious cardiovascular consequences” as 
PVP is not mentioned and no control for the C60 (e.g., carbon black mixed with PVP) was used. 
 
In detail, the experimental data reveal that the vehicle control has a z-average size of 
approximately 35 nm and the C60/PVP aggregate has a z-average of approximately 370 nm. After 
30 min, no size could be observed using DLS in the vehicle (PVP alone) whereas the aggregate 
PVP/C60 was still significantly larger (resulting in a sample nearly 1,000% larger than the vehicle 
control). The investigators show that these physical characteristics of PVP and C60/PVP are 
stable for over 38 min (the indicated length of the experiments). Although these stability results 
are important, a more comparable sized control is critical to accurately assess the impact of the 
C60fullerenes. Notwithstanding problems with experimental controls, a majority of the data 
presented by Thompson et al. provide readers with very little statistically significant results and 
some of the comparisons evaluated seem arbitrarily selected. For instance, one significant 
measurement describes the effect on protein concentration from PVP/C60 administered IT versus 
IV, a more substantial finding would be whether these results were significant against naïve or 
vehicle controls, which seems to have not been evaluated. However, in subsequent experiments 
the investigators do evaluate the significance between either PVP control or C60/PVP 
agglomerates versus naïve (as opposed to the IT vs. IV statistics examined earlier). Despite the 
seemingly selective statistical analysis, in most cases where significant results are revealed with 
C60/PVP the same outcomes are observed in PVP control versus naïve, revealing a somewhat 
convincing argument that PVP is inducing the observed deleterious consequences. 
 
The authors mention the potential for using fullerenes in medicine among many other 
applications. Indeed our group has published several studies using these molecules as 
therapeutics and diagnostics. We have demonstrated that highly purified, water soluble fullerene 
derivatives are not acutely toxic, are cleared from the body within 48 h, and in general have anti-
inflammatory properties.7–12 The likelihood that such a concoction of fullerenes used in the 
article by Thompson et al. would ever be used for any medical application (and injected at 
particle sizes used in this study) is non-existent. The FDA requires that every new chemical 
entity (NCE) must be evaluated separately; extrapolating toxicity (or non-toxicity) by 
categorizing compound mixtures and making generalizations about classes of compounds (as is 
the case in this study with fullerenes) with many different isomers is not acceptable to the FDA. 
Many studies have revealed that even extremely similar molecules can have different biologic 
activities, where two very similar isomers have completely different biological behavior. This 
applies to the studies with any molecule being evaluated for potential medical applications where 
even extremely small changes can result in the NCE having completely different biological 
properties. In potential fullerene derived therapies, any modifications to the core carbon structure 
(through the addition of side-chain moieties, coatings, etc.) must be thoroughly studied and 
evaluated to establish safety profiles. This has been demonstrated repeatedly by several 
laboratories, which highlight the difficulty in interpreting data gathered from extrapolating 
findings between even very similar compounds. Thompson et al. describe results from directly 
injecting insoluble material with millions of different aggregate sizes and isomers of C60 and 
PVP which make extrapolation into any medical application difficult. 
 
The concerns of toxicity have slowed the initial enthusiasm that surrounded the discovery of 
fullerenes. Although there are over 11,000 peer-reviewed publications on the NIH's National 
Library of Medicine (www.pubmed.gov) using fullerenes and over 4,000 granted fullerene 
patents according to the US Patent and Trademark Office (www.uspto.gov), no health-related 
diagnostic, therapeutic, or theranostic compound using fullerenes has reached the market in the 
United States. Only those studies using well-characterized, single species molecules, be it 
fullerenes or otherwise, can provide meaningful information regarding potential toxicological 
effects. Such studies are increasingly critical as the state of nanomedicine-based research today 
with fullerenes is shaped by studies that address the observation “that extrapolation across 
similar nanoparticles will be dependent upon surface chemistry and concentration which may 
affect the degree of agglomeration and thus biological effects”.13 Contributing to the confusion in 
the field is the continuous findings that C60-derivatives significantly extend the life of mammals 
and improve cognition.14,15 It is difficult for scientists and non-scientists to interpret how a 
material that significantly extends the life of an animal can simultaneously be toxic as suggested 
here. As more studies make erroneous conclusions such as those presented here, the likelihood 
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